The Department of Hematology of Liaocheng Second People's Hospital was established in 1995, with 12 doctors: 2 chief physicians, 3 deputy chief physicians, 3 attending physicians and 4 residents. It has a solid foundation of clinical internal medicine work and has accumulated rich experience in the treatment of blood diseases. The department has 35 beds, which is specially set up for hematologic patients to undergo comprehensive treatment such as chemotherapy, biotargeted therapy, and combination of traditional Chinese and Western medicine in order to eliminate residual lesions and prevent recurrence and metastasis as well as to prolong the survival time of inoperable late-stage patients and to improve their quality of life. There are more than 10 sets of large equipment such as sterile beds, electrocardiographic monitors, bone marrow image workstations, short-wave ultraviolet therapy, anti-embolism pumps and so on.

   Specialty Clinic:

Specializing in the treatment of various blood diseases: the Department of Hematology has been declared as a key clinical specialty in Liaocheng City, equipped with a special hematology laboratory, which provides highly targeted and specialized treatment for various anemia, blood tumors, bleeding disorders, thrombotic disorders, and difficult internal medicine diseases with prolonged fever. The Department of Hematology constantly learns advanced diagnosis and treatment techniques at home and abroad, and carries out a variety of high-end examination and treatment programs, such as leukemia immunophenotyping, bone marrow karyotype analysis, leukemia micro-residual detection, etc.; leukemia shelter clearing, Vanco treatment of multiple myeloma, Fotavax treatment of chronic gonorrhea, lymphoma biotherapy, and slow granulocyte targeted therapy, etc., which have achieved good clinical efficacy. In particular, the application of standard combination chemotherapy for acute leukemia has resulted in a 70% long-term survival rate for some patients (e.g., M3), as well as the application of immunosuppressants combined with male hormones, etc., for the treatment of severe aplastic anemia and chronic aplastic anemia have achieved good efficacy.

Hematology consultation and treatment is characterized by standardized, rational and individualized treatment plans based on each patient's constitution, pathological type and lesion staging, which greatly improves the quality of life of patients, reduces recurrence and mortality rates, and increases the disease-free survival rate and overall survival rate of patients.